Hitgen 成都先导
12 significant filings since 29 May 2026: 6 on equity incentive, 3 on major holder selling and 2 on change of interest, and 1 other kind. The latest, on 24 Sep 2026: 成都先导药物开发股份有限公司关于2025年限制性股票激励计划第一个归属期归属结果暨股票上市公告.
自 29 May 2026 起有 12 份重大公告：equity incentive 6 份、major holder selling 3 份、change of interest 2 份，另有 1 类。最新一份（24 Sep 2026）：成都先导药物开发股份有限公司关于2025年限制性股票激励计划第一个归属期归属结果暨股票上市公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 14 Feb 2024 | 民生证券 | 王班 | Neutral 中性 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 国信证券 | 陈曦炳,彭思宇,肖婧舒 | Outperform 增持 | 6 Sep 2026 | 3 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。